Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

被引：0
|
作者：
S. H. Waters
A. Gillibrand
H. Berry
S. Kumar
G. Velikova
D. J. Dodwell
Timothy J. Perren
机构：
[1] St James’s Institute of Oncology,
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Anthracyclines; Antineoplastic combined chemotherapy protocols; Breast neoplasms; Capecitabine; Taxoids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：407 / 412
页数：5
相关论文
共 50 条
  • [31] Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL
    Di Costanzo, F
    Gasperoni, S
    Papaldo, P
    Bilancia, D
    Manzione, L
    Landucci, E
    Mazzoni, F
    Cognetti, F
    ANNALS OF ONCOLOGY, 2006, 17 (01) : 79 - 84
  • [32] Weekly paclitaxel in elderly patients with advanced breast cancer: A dose-finding study
    Repetto L.
    Comandini D.
    Mammoliti S.
    Pietropaolo M.
    del Mastro L.
    Drugs in R & D, 2004, 5 (1) : 11 - 15
  • [33] Dose-finding study of the combination of oral idarubicin and oral capecitabine in the treatment of locally advanced or advanced breast cancer
    Nussey, F.
    Afseth, J.
    Murray, E.
    Bowman, A.
    Leonard, R.
    Cameron, D.
    EJC SUPPLEMENTS, 2004, 2 (03): : 137 - 137
  • [34] Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer
    Kurtz, JE
    Deplanque, G
    Borel, C
    Mathelin, C
    Prévost, G
    Poulin, G
    Barats, JC
    Bergerat, JP
    Chapelle-Marcillac, I
    Bardonnet, M
    Dufour, P
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 229 - 230
  • [35] Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer
    Culine, Stephane
    Terret, Catherine
    Cupissol, Didier
    Romieu, Gilles
    Fabbro, Michel
    Pouessel, Damien
    Droz, Jean-Pierre
    Gourgou, Sophie
    JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (02) : 122 - 127
  • [36] High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer
    Milla-Santos, A
    Rallo, L
    Solano, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (02): : 138 - 142
  • [37] A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer
    Park, Inkeun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Kang, Myoung Joo
    Lee, Changsuk
    Park, Young Soo
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [38] Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study
    Zeuli, M
    Di Costanzo, F
    Sdrobolini, A
    Gasperoni, S
    Paoloni, FP
    Carpi, A
    Moscetti, L
    Cherubini, R
    Cognetti, F
    ANNALS OF ONCOLOGY, 2001, 12 (12) : 1737 - 1741
  • [39] Phase I intrapatient dose escalation study of weekly epirubicin and docetaxel as first line chemotherapy in metastatic breast cancer
    Lo, N.
    Ayers, S.
    Catell, E.
    Koetzl, B.
    Singh, N.
    Alexander, G.
    Lowe, F.
    Rea, D. W.
    EJC SUPPLEMENTS, 2004, 2 (03): : 133 - 133
  • [40] Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer
    Amarantidis, K.
    Xenidis, N.
    Chelis, L.
    Chamalidou, E.
    Dimopoulos, P.
    Michailidis, P.
    Tentes, A.
    Deftereos, S.
    Karanikas, M.
    Karayiannakis, A.
    Kakolyris, S.
    ONCOLOGY, 2011, 80 (5-6) : 359 - 365
12345